Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Exagen Inc.NASDAQ: XGN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $599K rose 36.1% year over year, ahead of the +24.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at +10.8% a year.
Context
- Depreciation & amortization amounted to 3.2% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +36.1% holds above the trailing-twelve-month pace of +24.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 2.12M USD
- Year-over-year change
- +22.9%
- 4-year CAGR
- +22.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.12M | +22.9% |
| FY2024 | 2024-12-31 | 1.72M | -20.5% |
| FY2023 | 2023-12-31 | 2.17M | +39.2% |
| FY2022 | 2022-12-31 | 1.56M | +64.2% |
| FY2021 | 2021-12-31 | 948K | — |
Depreciation & Amortization vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 depreciation & amortization of $2.13M is the 7th highest of the 11 companies compared; the peer median is $4.66M.
- Its year-over-year change of +24.9% is the 4th highest of 10, against a peer median of +7.3%.
- Depreciation & amortization amounts to 3.1% of revenue for XGN, versus a peer median of 6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.46M | -8.0% | -0.8% | 8.5% | |
| LTM Mar 2026 | $13.46M | +95.4% | +63.4% | 6.2% | |
| LTM Mar 2026 | $9.77M | — | -23.7% | 7.2% | |
| FY2025 | $9.21M | +14.5% | +23.3% | 8.5% | |
| LTM Mar 2026 | $6.34M | -2.8% | +26.1% | 15.2% | |
| LTM Mar 2026 | $2.98M | -39.7% | +3.9% | 2.8% | |
| LTM Mar 2026 | $2.13M | +24.9% | +10.8% | 3.1% | |
| LTM Mar 2026 | $1.59M | +32.8% | +53.6% | 5.1% | |
| LTM Mar 2026 | $528K | +7.3% | -17.1% | 6.3% | |
| LTM Mar 2026 | $441K | -24.4% | -27.0% | 0.6% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K | +39.8% | +18.2% | 2.3% |
| Peer median (excluding XGN) | $4.66M | +7.3% | +11.1% | 6.2% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.3M | 45.56M | 52.55M | 55.64M | 66.58M |
| Cost of Revenue | 20.59M | 24.21M | 23.09M | 22.53M | 27.78M |
| Gross Profit | 27.71M | 21.35M | 29.46M | 33.11M | 38.8M |
| Gross Margin | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% |
| Research & Development | 7.24M | 9.88M | 4.87M | 5.38M | 6.25M |
| Selling, General & Admin | 44.54M | 52.02M | 47.43M | 41.37M | 46.62M |
| Operating Expenses | 51.78M | 67.4M | 52.29M | 46.75M | 52.87M |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| EBITDA | (23.1M) | (43.66M) | (19.15M) | (11.15M) | (13.46M) |
| EBITDA Margin | -47.8% | -95.8% | -36.4% | -20.0% | -20.2% |
| Operating Income | (24.07M) | (46.05M) | (22.84M) | (13.64M) | (14.07M) |
| Operating Margin | -49.8% | -101.1% | -43.5% | -24.5% | -21.1% |
| Interest Income | 16K | 830K | 1.52M | 767K | 289K |
| Interest Expense | 2.63M | 2.45M | 2.34M | 2.23M | 4.32M |
| Other Income / Expenses | (2.61M) | (1.62M) | (819K) | (1.47M) | (5.83M) |
| Income Before Tax | (26.68M) | (47.67M) | (23.66M) | (15.1M) | (19.9M) |
| Pre-Tax Margin | -55.2% | -104.6% | -45.0% | -27.1% | -29.9% |
| Income Tax Expense | 175K | (282K) | 33K | 12K | 51K |
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Net Margin | -55.6% | -104.0% | -45.1% | -27.2% | -30.0% |
| EPS (Basic) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| EPS (Diluted) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| Weighted Avg Shares | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
| Weighted Avg Shares (Diluted) | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.